Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Moonshiner592on May 27, 2021 8:48pm
214 Views
Post# 33283645

RE:Update on the Reverse Spilt

RE:Update on the Reverse Spilt
Moonshiner592 wrote: This is from Bob:

Update on the Reverse Split:
 
The TSXV "five cent rule" comes back into effect on June 30.  After that we can't sell shares at a price of less than $0.05.
 
If our shares are trading at less than $0.05 after June 30, we will not be able to raise cash at all. There won't be funds for the Phase 1 or Phase 2 studies and won't have the resources to do anything at all.
 
Our bankers tell us that investors don't want to invest in $0.03 shares, but will invest in Shares trading above $0.50. So we need to do the RS to get above $0.50, so we can raise the cash we need.
 
Bob Farrell



All I can say is - Vote "Yes". 

We need those funds - granting of those funds will get us some green - we need that.

Not pumping here .. facts are facts - face it - and most of all get over it.!

 

 


 

<< Previous
Bullboard Posts
Next >>